Protocol summary

Study aim
To determine the effect of adding rosuvastatin to the standard Helicobacter pylori eradication regimen on the eradication rate.
Design
A phase 3, randomized, double blind, placebo controlled, parallel clinical trial will be conducted in 208 patients with one to one allocation. Block randomization with variable block sizes of 4 and 6 will be performed using Random Allocation Software.
Settings and conduct
The study will be conducted at Emam Khomeini Hospital in Ardabil. Rosuvastatin and placebo will be packaged and coded by an independent pharmacist. Participants and treating physicians will be blinded to group allocation, and the data analyst will remain blinded until completion of the final analysis.
Participants/Inclusion and exclusion criteria
Patients aged 18 years or older with upper gastrointestinal symptoms and Helicobacter pylori infection confirmed by stool antigen testing will be included. Major exclusion criteria include previous gastric surgery or eradication therapy, use of antibiotics, proton pump inhibitors, histamine receptor blockers, or nonsteroidal anti inflammatory drugs during the previous month, allergy to study antibiotics, gastrointestinal malignancy or bleeding, pregnancy, and breastfeeding.
Intervention groups
The intervention group will receive levofloxacin 500 milligrams daily, esomeprazole 40 milligrams every 12 hours, amoxicillin 2 grams daily, and rosuvastatin 20 milligrams daily for 14 days. The control group will receive the same standard regimen plus matching rosuvastatin placebo.
Main outcome variables
Helicobacter pylori eradication one month after completion of treatment, assessed by stool antigen testing.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20260929071236N1
Registration date: 2026-10-05, 1405/07/13
Registration timing: prospective

Last update: 2026-10-05, 1405/07/13
Update count: 0
Registration date
2026-10-05, 1405/07/13
Registrant information
Name
Mahsa Mahdavirad
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 45 3232 2382
Email address
mahsa.mahdavi٠٤٥@gamil.com
Recruitment status
recruiting
Funding source
Expected recruitment start date
2026-11-22, 1405/09/01
Expected recruitment end date
2027-08-21, 1406/05/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluating the Impact of Rosuvastatin as an Adjuvant to Helicobacter pylori Eradication Regimen on Eradication Rates in Patients with Positive Helicobacter Pylori
Public title
Effect of Rosuvastatin on Helicobacter pylori Eradication
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age 18 years or older Presence of upper gastrointestinal symptoms related to Helicobacter pylori infection Confirmed Helicobacter pylori infection based on stool antigen testing Provision of informed consent to participate in the study
Exclusion criteria:
History of gastric surgery History of previous Helicobacter pylori eradication therapy Use of antibiotics, proton pump inhibitors, histamine receptor blockers, or non-steroidal anti-inflammatory drugs during the previous month Known allergy to any of the antibiotics used in the study Presence of gastrointestinal malignancy Presence of gastrointestinal bleeding Pregnancy Breastfeeding
Age
From 18 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 208
Randomization (investigator's opinion)
Randomized
Randomization description
The unit of randomization is the individual participant. Eligible participants will be allocated to the intervention and control groups in a 1:1 ratio. Block randomization with variable block sizes of 4 and 6 will be used. The random allocation sequence will be generated using Random Allocation Software. No stratified randomization will be used. To ensure allocation concealment, rosuvastatin and matching placebo will be packaged and labeled with numerical codes by an independent pharmacist. The allocation codes will be kept by the independent pharmacist, and individuals involved in participant enrollment and clinical care will not have access to the contents of the coded packages. The allocation codes will remain concealed until completion of the final data analysis.
Blinding (investigator's opinion)
Double blinded
Blinding description
Participants, physicians and other clinical care providers, investigators, outcome assessors, and the data analyst will be blinded to participants' allocation to the intervention or control group. Rosuvastatin 20 mg and placebo without active ingredients will be prepared to be indistinguishable in appearance, color, size, and packaging. Preparation, packaging, and coding of the active drug and placebo will be performed by an independent pharmacist who will not be involved in participant enrollment, clinical care, outcome assessment, or data analysis. The medication packages will be identified only by numerical codes, and the information linking the codes to treatment allocation will be retained by the independent pharmacist. Participants, clinical care providers, investigators, and outcome assessors will not have access to the allocation code during the study. Data analysis will also be performed using coded study groups without the data analyst being aware of the assigned intervention. The allocation code will be revealed only after completion of the final data analysis.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Research Ethics Committees of Ardabil University of Medical Sciences
Street address
Vice-Chancellery for Research and Technology, Ardabil University of Medical Sciences, North Side of the University Administrative Complex, University Square, University Street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Approval date
2026-08-26, 1405/06/04
Ethics committee reference number
IR.ARUMS.REC.1405.163

Health conditions studied

1

Description of health condition studied
Helicobacter pylori infection
ICD-10 code
B98.0
ICD-10 code description
Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Primary outcomes

1

Description
Percentage of participants with successful eradication of Helicobacter pylori infection
Timepoint
One month after completion of the 14 day treatment course
Method of measurement
Helicobacter pylori stool antigen test

Secondary outcomes

1

Description
Percentage of participants experiencing at least one treatment related adverse event
Timepoint
At the follow up visit one month after completion of the 14 day treatment course
Method of measurement
Face to face interview with the participant using a predefined adverse event checklist including headache, epigastric pain, nausea, diarrhea, and other unwanted symptoms

Intervention groups

1

Description
Intervention group: Participants will receive the standard triple Helicobacter pylori eradication regimen for 14 days, consisting of oral levofloxacin 500 mg once daily, oral esomeprazole 40 mg every 12 hours, and a total of 2 g oral amoxicillin daily. In addition, they will receive oral rosuvastatin 20 mg once daily for 14 days.
Category
Treatment - Drugs

2

Description
Control group: Participants will receive the standard triple Helicobacter pylori eradication regimen for 14 days, consisting of oral levofloxacin 500 mg once daily, oral esomeprazole 40 mg every 12 hours, and a total of 2 g oral amoxicillin daily. In addition, they will receive one rosuvastatin placebo tablet daily for 14 days. The placebo will contain no active ingredient and will be matched to rosuvastatin in appearance, color, size, and packaging.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Emam Khomeini Hospital
Full name of responsible person
Shahriar Movasagh
Street address
Emam Khomeini Hospital, Shahid Noei Aghdam Brothers Street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3325 1401
Email
Emamhe@arums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Mohsen Arzanlou
Street address
Vice-Chancellery for Research and Technology, Ardabil University of Medical Sciences, North Side of the University Administrative Complex, University Square, University Street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3353 4757
Email
research@arums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ardabil University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Mahsa Mahdavirad
Position
Internal Medicine Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
Emam Khomeini Hospital, Shahid Noei Aghdam Brothers Street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3326 2140
Email
mahsa.mahdavi045@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Shahryar Movassagh
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Emam Khomeini Hospital, Shahid Noei Aghdam Brothers Street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3326 2140
Email
shahryarmovassagh@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Ardabil University of Medical Sciences
Full name of responsible person
Mahsa Mahdavirad
Position
Internal Medicine Resident
Latest degree
Medical doctor
Other areas of specialty/work
Internal Medicine
Street address
Emam Khomeini Hospital, Shahid Noei Aghdam Brothers Street
City
Ardabil
Province
Ardabil
Postal code
5618985991
Phone
+98 45 3326 2140
Email
mahsa.mahdavi045@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...